Skip to content
Aminoscope
Head-to-head

Pemvidutide vs Survodutide

The two GLP-1/glucagon dual agonists, both investigational, chasing different prizes: one is optimizing body composition, the other has already read out Phase 3.

By Julian RothResearch & dataUpdated November 2026

Short answer

Both have human clinical data behind them, which makes the goal the real difference between pemvidutide and survodutide. For a reader focused on weight loss and MASLD/MASH, pemvidutide is the relevant choice; survodutide is marketed for weight loss and MASH. Both are legitimately available only inside clinical trials.

Pemvidutide

Clinical data

The Pemvidutide evidence review explains what has been studied. A GLP-1/glucagon dual agonist aimed specifically at preserving lean mass while cutting liver fat; real Phase 2 MASLD data, but Phase 3 has not started and it remains fully investigational.

Survodutide

Clinical data

The Survodutide evidence review explains what has been studied. A GLP-1/glucagon dual agonist in Phase 3 for both obesity and MASH; genuine placebo-controlled efficacy data in both indications, but no approval anywhere yet.

Pemvidutide vs Survodutide: head to head

The evidence matrix shows the source behind each grade and the use that grade applies to. A grade for one use does not carry over to every claim about the same molecule.

FDA status / approved use

Pemvidutide

Investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 planned

Survodutide

Investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere
Marketed for

Pemvidutide

Weight loss, MASLD/MASH

Survodutide

Weight loss, MASH
Outcome areas

Pemvidutide

Weight loss / appetite; Liver / detox; Muscle / strength / lean mass

Survodutide

Weight loss / appetite; Liver / detox
Evidence grade

Pemvidutide

Clinical data

Survodutide

Clinical data
How it works

Pemvidutide

Dual GLP-1 and glucagon receptor agonist; glucagon arm stimulates liver fat oxidation

Survodutide

Activates GLP-1 and glucagon receptors to curb appetite and raise energy expenditure
Route and dosing

Pemvidutide

Once-weekly injection

Survodutide

Subcutaneous injection, once weekly
Headline human result

Pemvidutide

About −15.6% mean weight loss at 2.4 mg vs −2.2% on placebo over 48 weeks in the Phase 2 MOMENTUM trial (391 adults)

Survodutide

Mean weight change about −16.6% vs −3.2% on placebo at 76 weeks in the 2026 Phase 3 SYNCHRONIZE-1 trial
Strongest evidence

Pemvidutide

Survodutide

Key safety signal

Pemvidutide

No long-term safety data; glucagon action needs long-term cardiometabolic monitoring

Survodutide

Common, dose-related nausea, diarrhea and vomiting
How it is obtained

Pemvidutide

Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals

Survodutide

Legitimately available only inside clinical trials; vials sold online are gray-market research chemicals

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).

Our verdict

Survodutide is further along by a wide margin. Its Phase 3 SYNCHRONIZE-1 (n=725, 76 weeks) reported about −16.6% mean weight loss against −3.2% on placebo, and SYNCHRONIZE-MASLD (n=216) reported 84.2% of participants achieving at least a 30% reduction in liver fat with 61.0% normalizing it. Pemvidutide is still Phase 2: MOMENTUM (391 adults, 48 weeks) produced about −15.6% at 2.4 mg versus −2.2% on placebo, and its IMPACT Phase 2b trial met MASH resolution without worsening fibrosis at 24 weeks. Pemvidutide’s distinguishing claim is body composition — Altimmune reported roughly 74.5% of the weight lost was fat and 25.5% lean — but that is a company-reported ratio framed around the hypothesis the program was designed to test, not a finding another trial has confirmed, and it should not be read as an established advantage. Neither drug is approved anywhere.

Pemvidutide fits if

You care specifically about the lean-mass-preservation hypothesis and want to watch whether it survives a Phase 3 that has not started yet.

Survodutide fits if

You want the dual agonist with real Phase 3 data in both obesity and liver disease — the one likelier to reach a regulator first.

Pemvidutide vs Survodutide: common questions

Is either pemvidutide or survodutide FDA-approved?
No. Pemvidutide is investigational, not approved anywhere; Phase 2b complete, FDA Breakthrough Therapy Designation for MASH, Phase 3 planned. Survodutide is investigational; positive Phase 3 obesity and liver trials, not yet approved anywhere.
Which has stronger human evidence, pemvidutide or survodutide?
Neither clearly. Both have human clinical data. The key source for pemvidutide is phase 2 MASLD RCT, 2025; for survodutide, it is phase 2 obesity RCT, 2024.
What are the main safety concerns with pemvidutide and survodutide?
Pemvidutide has no long-term safety data; glucagon action needs long-term cardiometabolic monitoring. For survodutide, watch for common, dose-related nausea, diarrhea and vomiting.

Key studies behind each

Pemvidutide

  1. Harrison SA, Browne SK, Suschak JJ, et al. (2025). Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. PubMed 39002641
  2. Noureddin M, Harrison SA, Loomba R, et al. (2025). Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. PubMed 41237796

Survodutide

  1. le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. (2024). Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. PubMed 38330987
  2. Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, et al. (2024). A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. PubMed 38847460

The full evidence reviews

Related comparisons